- Home
- NPCT vs CAPR Comparison
NPCT vs CAPR Comparison
Compare NPCT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- CAPR
- Stock Information
- Founded
- NPCT 2020
- CAPR 2005
- Country
- NPCT United States
- CAPR United States
- Employees
- NPCT N/A
- CAPR N/A
- Industry
- NPCT Investment Managers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCT Finance
- CAPR Health Care
- Exchange
- NPCT Nasdaq
- CAPR Nasdaq
- Market Cap
- NPCT 314.6M
- CAPR 324.6M
- IPO Year
- NPCT N/A
- CAPR N/A
- Fundamental
- Price
- NPCT $10.91
- CAPR $6.28
- Analyst Decision
- NPCT
- CAPR Strong Buy
- Analyst Count
- NPCT 0
- CAPR 8
- Target Price
- NPCT N/A
- CAPR $24.75
- AVG Volume (30 Days)
- NPCT 107.1K
- CAPR 1.4M
- Earning Date
- NPCT 01-01-0001
- CAPR 08-11-2025
- Dividend Yield
- NPCT 9.82%
- CAPR N/A
- EPS Growth
- NPCT N/A
- CAPR N/A
- EPS
- NPCT N/A
- CAPR N/A
- Revenue
- NPCT N/A
- CAPR $13,392,150.00
- Revenue This Year
- NPCT N/A
- CAPR N/A
- Revenue Next Year
- NPCT N/A
- CAPR $6,061.53
- P/E Ratio
- NPCT N/A
- CAPR N/A
- Revenue Growth
- NPCT N/A
- CAPR N/A
- 52 Week Low
- NPCT $8.58
- CAPR $3.98
- 52 Week High
- NPCT $10.63
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- NPCT 48.99
- CAPR 36.33
- Support Level
- NPCT $10.82
- CAPR $6.17
- Resistance Level
- NPCT $10.98
- CAPR $7.30
- Average True Range (ATR)
- NPCT 0.12
- CAPR 0.43
- MACD
- NPCT -0.01
- CAPR -0.11
- Stochastic Oscillator
- NPCT 48.15
- CAPR 4.53
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.